Health economic assessment: Cost-effectiveness thresholds and other decision criteria

International Journal of Environmental Research and Public Health

Volumn 7, Issue 4, 2010, Pages 1835-1840

  Simoens, Steven ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Cost effectiveness; Cost effectiveness threshold; Decision criteria; Economic evaluation; Health economics; Multi criteria decision analysis; Opportunity cost

Indexed keywords

BUDGET; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; ECONOMIC EVALUATION; EVIDENCE BASED MEDICINE; HEALTH CARE; HEALTH ECONOMICS; LETTER; NEW ZEALAND; REIMBURSEMENT; COST BENEFIT ANALYSIS; HEALTH CARE COST;

COST-BENEFIT ANALYSIS; DECISION MAKING; HEALTH CARE COSTS; NEW ZEALAND;

EID: 77954559862     PISSN: None     EISSN: 16604601     Source Type: Journal    
DOI: 10.3390/ijerph7041835     Document Type: Letter

References (10)

1. Perleth, M.; Jakubowski, E.; Busse, R. What is 'best practice' in health care? State of the art and perspectives in improving the effectiveness and efficiency of the European health care systems. Health Policy 2001, 56, 235-250.
2. Simoens, S. Health economic assessment: a methodological primer. Int. J. Environ. Res. Public Health 2009, 6, 2950-2966.
3. Metcalfe, S.; Grocott, R. Health economic assessment: New Zealand in fact has no cost-effectiveness threshold. Int. J. Environ. Res. Public Health 2010, in press.
4. Weinstein, M.C.; Zeckhauser, R. Critical ratios and efficient allocation. J. Public Econ. 1973, 2, 147-157.
5. Sendi, P.; Gafni, A.; Birch, S. Opportunity costs and uncertainty in the economic evaluation of health care interventions. Health Econ. 2002, 11, 23-31.
6. European Commission Regulation (EC) No 141/2000 of the European Parliament and the Council of 16 December 1999 on orphan medicinal products. Official Journal of the European Communities 2000, L 18/1.
7. Denis, A.; Simoens, S.; Fostier, C.; Mergaert, L.; Cleemput, I. Health Technology Assessment Policy Governing Orphan Diseases and Orphan Medicines; Belgian Health Care Knowledge Centre: Brussels, Belgium, 2009.
8. Drummond, M.; Evans, B.; LeLorier, J.; Karakiewicz, P.; Martin, D.; Tugwell, P.; MacLeod, S. Evidence and values: requirements for public reimbursement of drugs for rare disease-a case study in oncology. Can. J. Clin. Pharmacol. 2009, 16, e273-e281.
9. Timoney, A.; Walker, A.; Paterson, K.; Bennie, M.; McIver, L.; Webb, D. The Scottish Medicine Consortium-are oncology medicines different? Presentation at the Third Health Technology Assessment International Conference, Adelaide, Australia, 2006.
10. Baltussen, R.; Niessen, L. Priority setting of health interventions: the need for multi-criteria decision analysis. Cost. Eff. Resour. Alloc. 2006, 4, 14.